ProMIS Neurosciences is trading at $14.32, up 7.43%, as unexpectedly weak July payrolls increased expectations for Federal Reserve rate cuts, favoring growth-oriented assets.
- Reuters reported U.S. stocks rose as the jobs data cast doubt on a September rate hike.
- Biotech advanced 2.09%, while enthusiasm following ProMIS’s positive PMN310 interim data likely provided additional support.
- No new company-specific announcement was identified for August 7, 2026.